Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Resmed (RSMDF) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Resmed (RSMDF) over the last 17 years, with Q4 2025 value amounting to -$258.3 million.

  • Resmed's Cash from Financing Activities fell 7510.68% to -$258.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$796.6 million, marking a year-over-year increase of 2247.33%. This contributed to the annual value of -$606.3 million for FY2025, which is 4583.58% up from last year.
  • Per Resmed's latest filing, its Cash from Financing Activities stood at -$258.3 million for Q4 2025, which was down 7510.68% from -$230.3 million recorded in Q3 2025.
  • Over the past 5 years, Resmed's Cash from Financing Activities peaked at $932.9 million during Q4 2022, and registered a low of -$393.3 million during Q2 2024.
  • Over the past 5 years, Resmed's median Cash from Financing Activities value was -$154.8 million (recorded in 2021), while the average stood at -$109.6 million.
  • As far as peak fluctuations go, Resmed's Cash from Financing Activities plummeted by 96199.43% in 2021, and later soared by 52798.77% in 2022.
  • Resmed's Cash from Financing Activities (Quarter) stood at -$218.0 million in 2021, then soared by 527.99% to $932.9 million in 2022, then crashed by 125.61% to -$239.0 million in 2023, then skyrocketed by 38.26% to -$147.5 million in 2024, then tumbled by 75.11% to -$258.3 million in 2025.
  • Its Cash from Financing Activities was -$258.3 million in Q4 2025, compared to -$230.3 million in Q3 2025 and -$163.9 million in Q2 2025.